
Mei Kim Ang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8717418/publications.pdf Version: 2024-02-01



MELKIM ANC

#	Article	IF	CITATIONS
1	Concurrent Chemo-Radiation With or Without Induction Gemcitabine, Carboplatin, and Paclitaxel: A Randomized, Phase 2/3 Trial in Locally Advanced Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 91, 952-960.	0.8	197
2	Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10â€year update and subset analysis. Cancer, 2015, 121, 1599-1607.	4.1	163
3	Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Nature Medicine, 2017, 23, 1167-1175.	30.7	141
4	Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer, 2020, 139, 207-215.	2.0	79
5	Advances in systemic treatment for nasopharyngeal carcinoma. Chinese Clinical Oncology, 2016, 5, 21-21.	1.2	69
6	EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. Journal of Thoracic Oncology, 2017, 12, 529-538.	1.1	57
7	Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC. Journal of Thoracic Oncology, 2020, 15, 1928-1934.	1.1	30
8	Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. PLoS ONE, 2015, 10, e0123587.	2.5	30
9	Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer. JAMA Network Open, 2021, 4, e2131892.	5.9	25
10	A Decade of Never-smokers Among Lung CancerÂPatients—Increasing Trend and ImprovedÂSurvival. Clinical Lung Cancer, 2018, 19, e539-e550.	2.6	21
11	Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer, 2018, 18, 1198.	2.6	18
12	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). PLoS ONE, 2019, 14, e0224665.	2.5	17
13	Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. Lung Cancer, 2015, 88, 289-296.	2.0	16
14	Imaging features of renal complications after crizotinib treatment for non–small-cell lung cancer: a case report. Radiology Case Reports, 2016, 11, 245-247.	0.6	14
15	Outcomes and Prognostic Factors of Radiationâ€Induced and De Novo Head and Neck Squamous Cell Carcinomas. Otolaryngology - Head and Neck Surgery, 2016, 154, 880-887.	1.9	11
16	A three gene immunohistochemical panel serves as an adjunct to clinical staging of patients with head and neck cancer. Oncotarget, 2017, 8, 79556-79566.	1.8	11
17	Metronomic chemotherapy: A relook at its basis and rationale. Cancer Letters, 2017, 388, 328-333.	7.2	10
18	Interactions between clinical factors, p16, and cyclin-D1 expression and survival outcomes in oropharyngeal and hypopharyngeal squamous cell carcinoma. Head and Neck, 2015, 37, 1650-1659.	2.0	9

Mei Kim Ang

#	Article	IF	CITATIONS
19	Germline hemizygous deletion of CDKN2A–CDKN2B locus in a patient presenting with Li–Fraumeni syndrome. Npj Genomic Medicine, 2016, 1, 16015.	3.8	9
20	Phase <scp>ll</scp> study of nimotuzumab (<scp>TheraCimâ€hR3</scp>) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. Head and Neck, 2021, 43, 1641-1651.	2.0	7
21	Pairing a prognostic target with potential therapeutic strategy for head and neck cancer. Oral Oncology, 2020, 111, 105035.	1.5	6
22	A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematology/ Oncology and Stem Cell Therapy, 2008, 1, 159-165.	0.9	4
23	Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study—An Asian Tertiary Cancer Center Experience. JCO Precision Oncology, 2021, 5, 859-875.	3.0	4
24	High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. International Journal of Radiation Oncology Biology Physics, 2020, 108, 70-80.	0.8	3
25	Twentyâ€five years of <i>Respirology</i> : Advances in lung cancer. Respirology, 2020, 25, 26-31.	2.3	2
26	Relationship between tumor response with outcomes in EGFR mutation positive (M+) non-small cell lung cancer (NSCLC) treated with tyrosine-kinase inhibitors (TKI) Journal of Clinical Oncology, 2014, 32, e19101-e19101.	1.6	0
27	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). , 2019, 14, e0224665.		0
28	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). , 2019, 14, e0224665.		0
29	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). , 2019, 14, e0224665.		0
30	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). , 2019, 14, e0224665.		0